Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
External and Internal Respiration01:24

External and Internal Respiration

External respiration occurs in the lungs, and it is the first step in the journey of oxygen inside the body. When we inhale, oxygen enters our lungs and diffuses across the thin alveolar membrane. The alveoli are tiny, air-filled sacs that provide a vast surface area for gas exchange. Oxygen in the alveoli has a higher partial pressure (105 mmHg) than in the adjacent pulmonary capillaries (40 mmHg), establishing a pressure gradient. As a result, oxygen molecules move from the alveoli into the...
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same author

What sotatercept can teach us about the right ventricle in pulmonary arterial hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement.

American journal of respiratory and critical care medicine·2026
Same author

Diagnostic and management dilemmas in pulmonary hypertension.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Comparison of Hemodynamic Responses to Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension in Japan and The Netherlands: A Multicenter Study.

Chest·2026

Related Experiment Video

Updated: Jul 3, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Low diffusion capacity in pulmonary hypertension.

Esther J Nossent1, Anton Vonk Noordegraaf

  • 1Department of Pulmonary Medicine, Amsterdam UMC, Free University Amsterdam, Amsterdam, Cardiovascular Sciences, Amsterdam, the Netherlands.

Current Opinion in Pulmonary Medicine
|July 2, 2026
PubMed
Summary
This summary is machine-generated.

Reduced diffusion capacity of the lungs for carbon monoxide (DLCO) is a key indicator in pulmonary hypertension diagnosis and prognosis. A severely decreased DLCO signals a worse outlook and aids in refining patient classification and treatment strategies.

Keywords:
COPD associated pulmonary hypertensioncTEPHconnective tissue disease associated pulmonary hypertensionhPpEFlung phenotype”pulmonary arterial hypertensionpulmonary hypertension associated with interstitial lung diseasepulmonary veno-occlusive disease

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method
08:44

Dual Test Gas Pulmonary Diffusing Capacity Measurement During Exercise in Humans Using the Single-Breath Method

Published on: February 2, 2024

Area of Science:

  • Pulmonary Medicine
  • Cardiology

Background:

  • Diffusion capacity of the lungs for carbon monoxide (DLCO) is a critical marker in pulmonary hypertension (PH).
  • Understanding DLCO's role is vital for accurate diagnosis and prognosis in various PH forms.

Purpose of the Study:

  • To review the diagnostic utility of DLCO in PH.
  • To explore the clinical implications, pathophysiology, and prognostic impact of reduced DLCO in PH.

Main Methods:

  • Literature review summarizing current evidence on DLCO in PH.
  • Analysis of diagnostic work-up and differential diagnoses for PH with reduced DLCO.

Main Results:

  • A significantly low DLCO in pulmonary arterial hypertension (PAH) warrants reconsideration of idiopathic PAH diagnosis.
  • Differential diagnoses include left heart disease, lung disease, CTEPH, CTD, and PVOD.
  • A severely decreased DLCO generally correlates with a poorer prognosis across different PH subtypes.

Conclusions:

  • Reduced DLCO enhances diagnostic accuracy and aids in phenotyping PH patients.
  • Integrating DLCO into routine assessments can improve disease classification and personalize treatment.
  • DLCO is crucial for identifying high-risk PH populations and guiding research efforts.